Antisense and RNAi Therapeutics Market Analysis

Antisense and RNAi Therapeutics Market Analysis

To get key market trends

  Download Free Sample

Based on technology, the market is segmented into RNA interference and antisense RNA. The RNA interference segment held the majority of market share in 2023 of about 62.4%.
 

• RNA interference segment dominates the market owing to its broader application spectrum compared to antisense RNA, making it more versatile and applicable across a wider range of therapeutic targets including viral infections, cancer, and certain genetic disorders.
   
• Increasing approval for RNA interference-based therapeutics by regulatory authorities has also made it more accessible for patients and health practitioners. For instance, US FDA approved Rivfloza in October 2023, an siRNA-based therapeutic for treating primary hyperoxaluria in adults.
   

Based on route of administration, the antisense and RNAi therapeutics market is classified into intravenous injections, intrathecal injections, subcutaneous injections, and other routes of administration. The intravenous injections segment dominated the market with a revenue of about USD 1.9 billion in 2023.
 

• Leading share of intravenous injections segment can be attributed to their significant use in delivering RNA interference-based therapeutics such as CALAA-01, MRX34, APN401, and siRNA-EphA2-DOPC.
   
• Furthermore, intravenous injections find widespread applications in the treatment of inaccessible targets such as systematic genetic disorders and certain types of cancers.
   
• Administering RNAi or antisense therapeutics through intravenous injections enables their systemic distribution throughout the body. This method of delivery allows the therapeutic agents to circulate in the bloodstream, enabling them to reach target tissues and cells located in various parts of the body.
   

Based on application, the antisense and RNAi therapeutics market is classified into cardiometabolic & renal disorders, cancer, neurodegenerative disorders, genetic disorders, infectious diseases, ophthalmic diseases, skin diseases, and other applications. The cardiometabolic & renal disorders segment secured a leading share of about 31.7% in 2023 and is anticipated to grow at 18.3% CAGR during the forecast period.
 

• Increasing prevalence of cardiometabolic and renal disorders such as liver fibrosis, diabetes, dyslipidemia, and chronic kidney disease are driving the demand for antisense and RNAi therapeutics in this segment, contributing to its leading share.
   

For instance, according to the International Diabetes Federation, about 537 million patients (20-79 years) had type -1 diabetes in 2021, which is expected to increase to 643 million by 2030.
 

• Increasing growth in approval of RNAi and antisense therapeutics targeted to treat liver related disorders has also contributed to dominating share of cardiometabolic & renal disorders segment. Liver's distinctive features make it an appealing target for RNA therapies, as they enhance the effective delivery and metabolism of medications.
   

North America antisense and RNAi therapeutics market accounted for 42.1% of market share in global market in 2023 and is predicted to reach USD 8.2 billion by 2032.
 

• Presence of large number of pharmaceutical manufacturers in the country offering advanced treatment options such as RNA therapies is driving the revenue growth in the region. Antisense and RNAi therapeutics manufacturers are leveraging their manufacturing expertise, research and development capabilities, and marketing strategies to maintain dominance in the regional market, which has eased the availability of advanced antisense and RNAi therapeutics-based treatment formulations in the region.
   
• Large number of approvals for RNA therapeutics by regulatory authorities such as U.S. FDA and Health Canada has eased the availability of advanced antisense and RNAi therapeutics covering wide range of diseases. For instance, in 2023, four therapeutic oligonucleotides received approval from U.S. FDA, including two antisense molecules, one RNA aptamer, and one siRNA.
   

The U.S. antisense and RNAi therapeutics market was valued at USD 1.6 billion in 2023 and is anticipated to grow at a CAGR of 18.1% over the forecast period.
 

• Increasing investments in RNA therapeutics-based clinical research and growing demand for personalized drug development is driving the revenue growth in the U.S. market. For instance, according to the American Society of Gene & Cell Therapy, in the first quarter of 2023, companies in the US signed 110 deals to promote advancements in gene and RNA therapies.  
   
• Availability of reimbursement and coverage for RNA-based therapeutics such as antisense and RNAi therapeutics is contributing to their increasing adoption in the country. The availability of reimbursement helps to reduce the out-of-pocket costs for patients which increases their access to treatment.
   

Germany antisense and RNAi therapeutics market is expected to show significant growth during the forecast period.
 

• Germany boasts one of the largest pharmaceutical markets in Europe, fostering a favorable environment for the advancement of Antisense and RNAi therapeutics research and development. According to Germany Trade & Invest (GTI), Germany stands out as a top contender in the European pharmaceutical market, evidenced by its significant investments in R&D, innovative initiatives, and patent applications. The availability of substantial investments for research and development in RNA therapeutics is propelling progress within the market in Germany.
   
• Moreover, the presence of advanced healthcare infrastructure in Germany, along with a rising healthcare expenditure, is also facilitating convenient access to medications like Antisense and RNAi therapeutics. As per the Federal Statistical Office of Germany (FSOG), healthcare spending in the nation reached approximately 13.2% of its GDP in 2021, which was 0.2% higher than 2020.
   

India antisense and RNAi therapeutics market is anticipated to grow remarkably over the coming years.
 

• Increasing growth in genetic disorders and chronic illnesses such as diabetes, cancer, and liver fibrosis, along with improved access to advanced treatment modalities such as antisense and RNAi therapeutics due to significant investments for expanding and modernizing healthcare infrastructure is driving the revenue growth in market in India.
   
• Moreover, owing to its large population, India has become one of the key destinations for clinical trials. Since the approval of first siRNA-based drug trial in 2016, RNA-based therapeutics are gaining increasing attention in the country leading to increased investments from both domestic and global pharmaceutical manufacturers for the development of advanced antisense and RNAi therapeutics.